Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing technologies and therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company is focused on neurological and psychiatric disorders, including orphan indications. Its lead programs are SLS-002, an intranasal racemic ketamine for the treatment of suicidality in post-traumatic stress disorder and in depressive disorder; and SLS-006, a partial dopamine agonist for monotherapy in early stage Parkinson's disease patients. The company was founded in 2016 and is based in New York, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-998-6475
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.76 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date10/30/2019 (Estimated)
OptionableNot Optionable
Seelos Therapeutics (NASDAQ:SEEL) Frequently Asked Questions
What is Seelos Therapeutics' stock symbol?
Seelos Therapeutics trades on the NASDAQ under the ticker symbol "SEEL."
How were Seelos Therapeutics' earnings last quarter?
Seelos Therapeutics Inc (NASDAQ:SEEL) announced its quarterly earnings results on Thursday, August, 1st. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.04. View Seelos Therapeutics' Earnings History.
When is Seelos Therapeutics' next earnings date?
What price target have analysts set for SEEL?
2 brokers have issued 12-month target prices for Seelos Therapeutics' stock. Their predictions range from $4.00 to $8.00. On average, they anticipate Seelos Therapeutics' stock price to reach $6.00 in the next year. This suggests a possible upside of 391.8% from the stock's current price. View Analyst Price Targets for Seelos Therapeutics.
What is the consensus analysts' recommendation for Seelos Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seelos Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seelos Therapeutics.
Has Seelos Therapeutics been receiving favorable news coverage?
Media headlines about SEEL stock have trended negative on Saturday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seelos Therapeutics earned a news sentiment score of -2.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Seelos Therapeutics.
Who are some of Seelos Therapeutics' key competitors?
Some companies that are related to Seelos Therapeutics include Vaccinex (VCNX), Savara (SVRA), Corvus Pharmaceuticals (CRVS), CELYAD SA/ADR (CYAD), Avenue Therapeutics (ATXI), Aduro BioTech (ADRO), Sunesis Pharmaceuticals (SNSS), Verastem (VSTM), Processa Pharmaceuticals (PCSA), Humanigen (HGEN), Aquinox Pharmaceuticals (AQXP), Aravive (ARAV), Millendo Therapeutics (MLND), Arbutus Biopharma (ABUS) and Trevena (TRVN).
What other stocks do shareholders of Seelos Therapeutics own?
Who are Seelos Therapeutics' key executives?
Seelos Therapeutics' management team includes the folowing people:
- Dr. Raj Mehra Ph.D., Chairman, CEO, Pres & Interim CFO (Age 59)
Who are Seelos Therapeutics' major shareholders?
Seelos Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (4.14%), Uniplan Investment Counsel Inc. (3.08%), BlackRock Inc. (1.39%), Vanguard Group Inc. (1.06%), A.R.T. Advisors LLC (0.23%) and Ardsley Advisory Partners LP (0.22%).
Which institutional investors are buying Seelos Therapeutics stock?
SEEL stock was bought by a variety of institutional investors in the last quarter, including Uniplan Investment Counsel Inc., Renaissance Technologies LLC, Vanguard Group Inc., BlackRock Inc., A.R.T. Advisors LLC, Wedbush Securities Inc., Citadel Advisors LLC and Northern Trust Corp.
How do I buy shares of Seelos Therapeutics?
Shares of SEEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Seelos Therapeutics' stock price today?
One share of SEEL stock can currently be purchased for approximately $1.22.
How big of a company is Seelos Therapeutics?
What is Seelos Therapeutics' official website?
How can I contact Seelos Therapeutics?
Seelos Therapeutics' mailing address is 300 PARK AVENUE 12TH FLOOR, NEW YORK NY, 10022. The company can be reached via phone at 646-998-6475 or via email at [email protected]
MarketBeat Community Rating for Seelos Therapeutics (NASDAQ SEEL)
MarketBeat's community ratings are surveys of what our community members think about Seelos Therapeutics and other stocks. Vote "Outperform" if you believe SEEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SEEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
